Protagonist Therapeutics, Inc.
PTGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.12 | -0.13 | 0.60 | -0.01 |
| FCF Yield | -0.05% | -0.84% | 4.10% | -1.23% |
| EV / EBITDA | -89.04 | -79.76 | -152.94 | 18.22 |
| Quality | ||||
| ROIC | -7.04% | -6.15% | -2.73% | 17.90% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 99.65% |
| Cash Conversion Ratio | 0.05 | 0.83 | -10.76 | -0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 5,936,425.31% | 5,936,075.33% | 523.09% | 153.78% |
| Free Cash Flow Growth | 93.16% | -123.71% | 523.28% | -2.97% |
| Safety | ||||
| Net Debt / EBITDA | 2.22 | 3.74 | 6.73 | -0.68 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 453.91 | 86.08 | 88.87 |